publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
viral
proteas
inhibitor
http
dx
earli
peopl
diagnos
across
world
sever
acut
respiratori
syndrom
sar
among
almost
die
due
first
outbreak
diseas
broken
turn
epidem
guangdong
south
china
two
case
sar
infect
notic
taiwan
singapor
due
improp
handl
sampl
research
laboratori
april
mini
outbreak
infect
took
place
research
laboratori
beij
turn
led
chain
infect
across
three
gener
fortun
total
number
sarsinfect
peopl
nine
time
incid
threaten
us
mini
outbreak
sar
global
time
anand
et
al
sar
caus
sarscoronaviru
sarscov
belong
famili
coronavirida
famili
also
includ
virus
felin
infecti
periton
viru
murin
hepat
viru
bovin
coronaviru
transmiss
gastroenter
viru
tgev
well
human
coronaviru
sar
consid
global
threat
health
khan
perlman
netland
moreov
water
foodborn
viral
gastroenter
may
caus
norovirus
belong
famili
calcivirida
atmar
patel
et
al
therefor
urgent
need
develop
small
molecul
antivir
drug
combat
virus
picornaviru
belong
famili
virus
name
picornavirida
calcivirida
coronavirida
mandadapu
et
al
number
pathogenes
human
may
occur
due
virus
lead
econom
medic
burden
exampl
human
rhinoviru
hrv
major
reason
viral
proteas
inhibitor
upper
respiratori
tract
infect
ren
et
al
turner
couch
winther
wherea
nonpolio
enterovirus
respons
symptomat
infect
million
case
per
year
unit
state
mcminn
solomon
et
al
depend
similar
polycistron
organ
genom
common
posttranscript
strategi
along
conserv
region
domain
homolog
viral
protein
viru
famili
relat
phylogenet
though
famili
relat
morpholog
anand
et
al
cavanagh
cowley
et
al
coronaviru
found
respons
caus
number
diseas
human
also
anim
though
human
coronaviru
taken
account
serious
sar
outbreak
anand
et
al
human
coronaviru
hcov
may
respons
ill
upper
portion
respiratori
tract
along
common
coldlik
condit
myint
hcov
strain
till
date
cultur
cell
cultur
techniqu
effici
symptom
sar
includ
rigor
malais
high
degre
fever
cough
headach
dyspnoea
symptom
may
also
lead
produc
interstiti
infiltr
lung
may
treat
ventil
intub
lung
also
organ
may
affect
sar
infect
liver
kidney
gastrointestin
tract
therefor
sar
infect
may
treat
caus
system
infect
facetofac
contact
may
suppos
reason
transmiss
pathogen
though
rout
also
possibl
number
inhibitor
sarscov
pro
hrv
pro
report
process
develop
new
antivir
class
continu
decad
present
report
quantit
structureact
relationship
qsar
techniqu
explor
understand
relat
sarscov
pro
hrv
pro
enzym
inhibitori
activ
physicochem
structur
properti
inhibitor
develop
till
approach
may
use
strategi
design
develop
novel
potenti
sarscov
pro
hrv
pro
inhibitor
combat
dread
viral
infect
sequenc
genom
structur
marra
et
al
rota
et
al
three
noncanon
pro
cleavag
site
observ
sar
coronaviru
polyprotein
val
met
phe
amino
acid
residu
posit
wherea
cleavag
site
found
dissimilar
coronavirus
therefor
structur
function
criteria
pro
help
identifi
import
target
develop
antisar
drug
anticoronavir
drug
anand
et
al
structur
hcov
pro
tgev
pro
sarscov
pro
demonstr
enzym
three
distinct
domain
first
two
domain
domain
ii
togeth
possess
similar
chymotrypsin
wherea
third
one
consist
fold
uniqu
anand
et
al
activ
site
situat
first
two
domain
possess
cyshi
catalyt
site
antiparallel
six
strand
compos
domain
ii
residu
ii
respect
domain
ii
connect
domain
iii
residu
long
loop
residu
anand
et
al
hydrophob
amino
acid
residu
found
compos
domain
residu
help
close
like
lid
domain
bigger
domain
ii
well
homolog
domain
ii
chymotrypsin
pro
hav
allair
et
al
bergmann
et
al
tsukada
blow
moreov
number
secondari
structur
element
found
miss
coronaviru
pro
compar
hav
pro
strand
cii
along
link
loop
form
portion
barrel
though
domain
ii
possess
maximum
consecut
turn
loop
moreov
structur
align
coronaviru
pro
domain
ii
picornaviru
pro
domain
ii
found
differ
superimposit
domain
tgev
pro
hav
pro
domain
result
root
mean
squar
deviat
rmsd
wherea
superimposit
domain
ii
enzym
yield
rmsd
overal
rmsd
c
atom
structur
c
posit
three
pro
structur
possess
similar
among
anand
et
al
helic
domain
iii
variabl
domain
exhibit
better
overlap
hcov
pro
tgev
pro
compar
sarscov
pro
moreov
tgev
hcov
belong
group
coronaviru
show
sequenc
similar
wherea
sarscov
belong
group
ii
coronaviru
exhibit
sequenc
similar
hcov
tgev
respect
high
degre
conserv
region
domain
ii
observ
compar
group
coronaviru
pro
group
ii
sarscov
pro
domain
iii
compar
exhibit
lower
degre
sequenc
similar
two
group
coronavir
enzym
anand
et
al
xray
crystallographi
structur
sarscov
pro
tgev
pro
hcov
pro
show
form
dimer
anand
et
al
yang
et
al
moreov
also
confirm
dimer
form
enzymat
activ
monomer
form
activ
anand
et
al
fan
et
al
dimer
process
found
mandatori
enzym
activ
process
help
discrimin
coronaviru
pro
picornaviru
pro
distinctli
catalyt
dyad
form
sarscov
activ
site
wherea
cystein
serin
proteas
found
form
catalyt
triad
water
molecul
found
hydrogen
bond
interact
moreov
cystein
residu
replac
serin
enzym
activ
site
enzymat
activ
sarscov
pro
decreas
coronavir
main
proteas
well
picornavir
proteas
cystein
residu
locat
place
activ
site
imidazol
ring
plane
distanc
hydrogen
bond
interact
side
chain
sulfur
atom
cystein
residu
along
plane
imidazol
function
anand
et
al
substrat
bind
site
found
conserv
coronaviru
main
proteas
suggest
experiment
observ
anand
et
al
xray
crystallograph
studi
inhibitorsar
cov
pro
suggest
viral
proteas
inhibitor
imidazol
function
locat
bottom
site
pro
donat
hydrogen
bond
backbon
carbonyl
function
glutamin
interact
glutamin
site
histidin
amino
acid
residu
remain
unalt
broad
rang
ph
may
possibl
two
interact
involv
imidazol
ring
may
either
stack
phenyl
ring
may
accept
hydrogen
bond
hydroxyl
function
replac
found
abolish
proteolyt
activ
hegyi
et
al
ziebuhr
et
al
residu
discuss
found
conserv
sarscov
pro
also
coronaviru
main
proteas
moreov
residu
pocket
take
part
conform
sarscov
pro
anand
et
al
regard
specif
site
coronavirus
pro
consist
leucin
residu
cleavag
site
site
hydrophob
natur
compos
side
chain
amino
acid
residu
longer
methionin
residu
may
restrict
pocket
requir
slight
spatial
orient
accommod
substrat
leucin
residu
due
presenc
residu
differ
amino
acid
sequenc
pocket
bigger
sarscov
pro
compar
hcov
pro
tgev
pro
sarscov
pro
stretch
amino
acid
sequenc
observ
residu
help
enlarg
size
form
helix
observ
coronavirus
bigger
size
may
effect
substrat
bind
anand
et
al
apart
pocket
substrat
bind
pocket
taken
consider
posit
small
amino
acid
residu
may
prefer
val
thr
ser
pro
wherea
specif
posit
observ
coronaviru
pro
posit
amino
acid
residu
found
conserv
sarscov
pro
moreov
amino
acid
side
chain
found
interact
main
chain
sarscov
pro
help
like
linker
domain
ii
iii
apart
antivir
fight
coronavirus
rna
interfer
rnai
vaccin
develop
may
use
strategi
though
challeng
task
rnai
import
tool
gene
silenc
apart
use
rnai
cancer
genet
disord
develop
sirna
inhibitor
sar
infect
may
boon
treatment
diseas
li
et
al
replic
sar
may
inhibit
effect
rnai
vero
cell
therefor
sirna
therapi
may
effect
combat
sar
infect
short
hairpin
rna
shrna
may
use
target
n
gene
sequenc
sar
coronaviru
inhibit
shrna
sarscov
antigen
express
tao
et
al
zhai
et
al
result
suggest
gene
silenc
rnai
may
effect
inhibit
sarscov
antigen
express
therefor
rnai
approach
may
effect
util
possibl
therapi
inhibit
sarscov
infect
moreov
rnai
use
target
replicas
enzym
human
sar
viru
target
hsar
gene
also
produc
inhibitori
effect
sar
rna
viru
express
zhai
et
al
far
develop
sar
vaccin
concern
inactiv
sarscov
along
fulllength
protein
attenu
weak
viru
recombin
sar
protein
may
use
jiang
et
al
zhai
et
al
protein
inactiv
viru
report
use
neutral
antibodi
attenu
weak
form
viru
might
use
induc
immun
well
neutral
antibodi
finlay
et
al
develop
recombin
vaccin
may
use
strategi
prevent
sar
infect
mainli
depend
best
antigen
identif
well
choic
express
system
glycoprotein
sarscov
along
truncat
form
may
target
develop
recombin
vaccin
best
candid
babcock
et
al
bisht
et
al
buchholz
et
al
yang
et
al
zhai
et
al
number
report
publish
regard
recombin
protein
vaccin
differ
sarscov
aryl
deliveri
system
pogrebnyak
et
al
tuboli
et
al
qsar
use
tool
understand
relat
structur
physicochem
properti
drug
molecul
biolog
activ
may
use
predict
activ
toxic
profil
drug
gupta
verma
hansch
data
requir
develop
qsar
model
collect
literatur
see
individu
qsar
correspond
refer
ic
molar
concentr
requir
produc
inhibit
enzym
ec
effect
concentr
k
bind
affin
data
obvious
consid
biolog
activ
term
depend
variabl
independ
variabl
includ
physicochem
paramet
hydrophob
molar
refract
dipol
moment
along
differ
axe
molecular
weight
mw
polar
surfac
area
psa
polar
volum
well
surfac
area
sa
volum
mani
topolog
paramet
kier
molecular
connect
indic
balaban
indic
etc
regard
statist
qsar
model
n
use
indic
number
compound
set
r
indic
correl
coeffici
qsar
model
obtain
r
refer
squar
correl
coeffici
exhibit
good
fit
q
indic
squar
leaveoneout
crossvalid
correl
coeffici
repres
intern
valid
model
r
refer
adjust
r
f
valu
repres
fischer
statist
fischer
ratio
actual
mean
ratio
explain
unexplain
varianc
particular
degre
freedom
p
stand
probabl
factor
relat
fratio
see
mean
standard
error
estim
q
qualiti
factor
measur
chanc
correl
high
q
repres
high
predict
well
lack
overfit
model
compound
misfit
correl
consid
outlier
usual
remov
regress
discuss
qsar
model
obtain
differ
categori
sarscov
pro
hrv
pro
inhibitor
model
suggest
increas
valu
psa
may
contribut
posit
bind
enzym
compound
higher
psa
compound
tabl
higher
activ
compound
lower
psa
compound
tabl
compound
lower
psa
higher
activ
wherea
compound
higher
psa
lower
activ
molecul
explain
properli
model
therefor
molecul
compound
tabl
consid
outlier
may
differ
mechan
action
blanchard
et
al
report
sarscov
pro
inhibitor
fig
tabl
qsar
model
compound
shown
eq
model
also
exhibit
psa
molecul
might
conduc
enzym
inhibitori
activ
compound
obviou
tabl
compound
higher
psa
higher
activ
compound
lower
psa
sulfon
amino
function
compound
disubstitut
amino
acid
function
compound
may
produc
higher
psa
compar
trichlorosubstitut
compound
monohydroxi
trifluoro
substitut
ester
analog
compound
also
suggest
enzymedrug
interact
might
take
place
nonhydrophob
space
enzym
activ
site
compound
lower
psa
possess
compar
higher
activ
compound
may
assum
compound
may
behav
differ
probabl
ester
function
chloro
group
may
electron
interact
enzym
respons
higher
inhibitori
activ
therefor
compound
may
consid
outlier
jain
et
al
synthes
evalu
ketoglutamin
analog
potent
sarscov
pro
inhibitor
tabl
seri
compound
qsar
model
obtain
shown
eq
equat
indic
paramet
use
valu
presenc
conm
absenc
group
valu
zero
neg
coeffici
suggest
compound
conm
function
compound
tabl
less
activ
compound
function
compound
tabl
therefor
compound
function
compound
prefer
higher
inhibitori
activ
shie
et
al
report
seri
potent
anilid
inhibitor
pro
fig
tabl
qsar
model
obtain
shown
eq
model
show
import
dipol
moment
along
xaxi
x
mw
psa
volum
vol
control
enzym
inhibit
posit
coeffici
dipol
moment
along
xaxi
suggest
bulki
substitut
along
xaxi
may
favor
activ
moreov
mw
also
shown
posit
impact
activ
wherea
psa
shown
neg
effect
therefor
may
suggest
molecul
bigger
size
along
bulki
substitu
may
conduc
inhibit
moreov
volum
found
parabol
relat
enzym
inhibit
optimum
valu
volum
compound
consid
outlier
molecul
may
work
differ
mechan
shie
et
al
report
seri
peptidomimet
unsatur
ester
promis
pro
inhibitor
tabl
qsar
model
obtain
shown
eq
observ
eq
increas
valu
mw
well
psa
may
detriment
activ
thu
model
suggest
smaller
molecul
less
steric
bulk
might
favor
activ
moreov
enzymedrug
interact
would
favor
nonhydrophob
space
observ
compound
unsatur
r
posit
compound
tabl
possess
lower
mw
compar
molecul
dataset
possess
higher
inhibitori
activ
compound
phenyl
ring
might
accommod
pocket
moreov
dimethylamino
cinnamyl
function
adopt
coplanar
rigid
structur
end
termin
may
help
form
hydrogen
bond
amino
acid
residu
enzym
activ
site
compound
may
behav
differ
henc
consid
outlier
wu
et
al
report
benzotriazol
ester
promis
pro
mechanismbas
inhibitor
tabl
model
obtain
seri
shown
eq
observ
eq
increas
valu
dipol
moment
along
yaxi
may
lead
decreas
activ
wherea
increas
valu
mw
may
conduc
activ
also
suggest
compound
higher
molecular
bulk
lower
steric
effect
may
favor
higher
inhibitori
activ
compound
ester
function
compound
tabl
better
activ
compound
acetyl
function
compound
molecul
compound
possess
higher
bulki
therefor
may
assum
ester
analog
impart
less
steric
effect
enzym
henc
produc
higher
activ
chen
et
al
report
divers
chemic
entiti
virtual
screen
surfac
plasmon
reson
fluoresc
reson
energi
transfer
base
assay
promis
sarscov
pro
fig
tabl
qsar
model
obtain
shown
eq
observ
eq
increas
valu
psa
may
detriment
activ
thu
suggest
less
polar
molecul
may
better
inhibitori
activ
due
presenc
electroneg
function
carboxyl
chloro
etc
molecul
may
larger
psa
compound
tabl
though
possess
lower
psa
higher
activ
could
explain
model
thu
compound
might
suppos
involv
differ
mechan
action
produc
higher
activ
therefor
compound
consid
outlier
zhou
et
al
report
isatin
analog
sarscov
pro
inhibitor
tabl
correl
obtain
eq
observ
eq
increas
sa
molecul
may
impart
higher
inhibitori
activ
bulki
substitut
r
posit
compound
tabl
may
impart
higher
sa
henc
produc
higher
activ
thu
substitut
conh
function
r
posit
place
iodo
function
may
better
effect
compound
vs
compound
vs
compound
vs
tabl
similarli
bulki
aryl
function
may
favor
alkyl
function
larger
sa
may
help
molecul
occupi
space
enzym
activ
site
better
bind
interact
evidenc
molecular
dock
analysi
zhou
et
al
compound
maximum
sa
exhibit
hydrogen
bond
keto
function
isatin
moieti
moreov
carboxamid
function
r
posit
make
hydrogen
bond
moieti
compound
fit
well
hydrophob
pocket
wherea
smaller
less
bulki
substitu
methyl
compound
npropyl
compound
nbutyl
compound
benzyl
compound
accommod
well
pocket
clear
compound
behav
aberrantli
though
possess
compar
good
sa
therefor
compound
may
consid
outlier
tsai
et
al
report
seri
sarscov
pro
inhibitor
pharmacophor
map
virtual
screen
approach
fig
tabl
qsar
model
obtain
shown
eq
p
see
q
q
outlier
compound
observ
eq
increas
valu
molar
refract
cmr
decreas
valu
dipol
moment
along
yaxi
well
volum
vol
may
contribut
posit
enzym
inhibitori
activ
therefor
suggest
increas
total
molecular
bulk
may
increas
activ
wherea
bulki
substitu
along
yaxi
may
detriment
activ
bulki
substitut
along
yaxi
may
produc
unfavor
steric
interact
enzym
therefor
bulki
molecul
less
steric
effect
may
favor
activ
compound
tabl
may
act
differ
mechan
action
henc
consid
outlier
tabl
structurebas
drug
design
approach
qsar
model
obtain
shown
eq
observ
equat
increas
valu
sa
polar
volum
pol
vol
may
conduc
activ
wherea
increas
valu
volum
dipol
moment
along
xaxi
x
might
detriment
activ
thu
could
suggest
bulki
substitut
along
xaxi
might
produc
unfavor
steric
hindranc
may
lower
activ
moreov
model
also
reveal
compound
higher
polar
volum
may
favor
activ
compar
compound
lower
polar
volum
compound
tabl
one
nitro
group
closer
imidazol
function
thu
may
electrostat
interact
lead
better
activ
moreov
phenyl
ring
may
form
interact
enzym
activ
site
lead
potent
activ
compound
tabl
might
act
differ
manner
henc
consid
outlier
chen
et
al
report
analog
promis
sarscov
pro
inhibitor
tabl
qsar
model
obtain
eq
observ
eq
decreas
valu
psa
would
posit
effect
biolog
activ
meant
less
polar
molecul
would
prefer
high
polar
molecul
due
presenc
number
hydroxyl
group
molecul
may
interact
enzym
hydrogen
bond
acceptor
molecular
model
studi
reveal
side
chain
form
four
hydrogen
bond
compound
tabl
wherea
two
hydrogen
bond
interact
observ
nitrogen
atom
howev
observ
compound
highest
psa
valu
due
presenc
two
galactos
ring
less
activ
probabl
compound
might
behav
aberr
fashion
henc
consid
outlier
zhang
et
al
synthes
evalu
phthalhydrazid
keton
tabl
heteroatom
ester
potenti
pro
inhibitor
qsar
model
develop
set
compound
shown
eq
eq
suggest
high
polar
volum
compound
would
favor
activ
molecular
model
studi
reveal
halopyridin
moieti
compound
well
accommod
bind
pocket
could
van
der
waal
interact
moreov
observ
halogen
atom
interact
enzym
direct
toward
solvent
expos
area
furyl
group
compound
locat
near
catalyt
residu
hydrophob
interact
compound
misfit
correl
exclud
ghosh
et
al
report
peptidomimet
sarscov
pro
inhibitor
tabl
qsar
model
obtain
z
observ
eq
increas
valu
dipol
moment
along
zaxi
z
lead
decreas
enzym
inhibitori
activ
thu
suggest
bulki
substitu
along
zaxi
conduc
activ
long
chain
linear
aminobutoxi
deriv
compound
tabl
better
isoxazol
analog
compound
tabl
isoxazol
moieti
may
produc
bulki
may
impart
unfavor
steric
effect
enzym
zhang
et
al
report
arylmethylen
keton
fluorin
methylen
keton
sarscov
pro
inhibitor
tabl
qsar
model
shown
eq
indic
variabl
stand
valu
uniti
ester
group
posit
coeffici
suggest
ester
group
may
favor
impart
higher
inhibitori
activ
compound
bear
ester
function
compound
tabl
highli
activ
compar
nonest
deriv
compound
tabl
compound
found
orient
pocket
furan
oxygen
atom
form
hydrogen
bond
amino
function
moreov
observ
compound
though
ester
function
may
behav
aberr
fashion
therefor
consid
outlier
qsar
model
obtain
seri
chloropyridin
ester
report
niu
et
al
potent
sarscov
pro
inhibitor
tabl
shown
eq
suggest
increas
molar
refract
decreas
total
dipol
moment
may
favor
proteas
inhibitori
activ
also
suggest
smaller
molecul
less
steric
effect
may
conduc
inhibitori
activ
compound
tabl
function
compound
tabl
ar
posit
yield
less
dipol
moment
better
molar
refract
compar
nitrophenyl
compound
chlorophenyl
compound
viral
proteas
inhibitor
pyridyl
analog
compound
thu
compound
potent
compound
furyl
deriv
compound
better
inhibitor
compar
aryl
ester
analog
compound
higher
molar
refract
despit
compar
moder
bulki
pchlorophenyl
pnitrophenyl
group
r
posit
slight
reduct
activ
notic
disubstitut
aryl
function
compound
alter
nitro
function
posit
phenyl
ring
compound
contrast
posit
compound
increas
bulki
total
bulk
reduc
activ
slightli
observ
molecular
model
studi
increas
length
side
chain
may
increas
interact
pocket
inhibitor
reflect
qsar
model
compound
possess
higher
molar
refract
compound
possess
lowest
valu
total
dipol
moment
reflect
activ
probabl
compound
behav
differ
compound
dataset
henc
outlier
yang
et
al
report
cinanserin
analog
sarscov
pro
inhibitor
tabl
qsar
model
obtain
shown
eq
equat
clearli
exhibit
high
molecular
volum
favor
activ
thu
compound
aryl
compound
heteroaryl
compound
long
chain
amid
function
compound
posit
lower
activ
compound
posit
unsatur
compound
ester
function
compound
compound
enter
deep
pocket
hydrophob
interact
howev
compound
lowest
volum
show
highest
activ
probabl
compound
compound
may
behav
differ
manner
enzym
henc
consid
outlier
qsar
model
deriv
trifluoromethyl
benzothiazolyl
thiazolyl
keton
compound
peptid
side
chain
report
regnier
et
al
eq
show
enzym
inhibitori
activ
correl
polar
volum
molecul
parabol
relat
therefor
suggest
activ
would
decreas
upto
optimum
valu
polar
volum
pol
vol
opt
beyond
start
increas
compound
function
compound
tabl
possess
higher
polar
volum
henc
possess
maximum
inhibit
compar
activ
compound
compound
may
suggest
function
compound
favor
diethylamino
function
compound
morpholino
function
compound
x
posit
moreov
function
compound
favor
thiazol
function
compound
bulki
group
morpholino
compound
benzylmethylamino
function
compound
favor
smaller
substitu
hydroxyl
compound
amino
group
compound
diethylamino
group
compound
x
posit
compar
compound
may
infer
bulki
amino
acid
moieti
compound
favor
smaller
amino
acid
function
compound
bulki
function
may
produc
higher
polar
volum
molecular
model
studi
reveal
benzyloxycarbonyl
moieti
compound
make
hydrophob
interact
rather
hydrogen
bond
interact
adjac
amino
function
ramajayam
et
al
report
pyrazolon
analog
promis
sarscov
pro
inhibitor
tabl
qsar
model
obtain
eq
thu
suggest
increas
valu
hydrophob
molecul
may
detriment
activ
compound
smaller
halogen
substitut
fluorin
r
posit
compound
tabl
better
compound
bigger
halogen
substitu
chloro
compound
tabl
dihalo
substitut
compound
compound
shown
less
activ
compar
monohalosubstitut
analog
compound
cyano
compound
nitro
compound
substitut
also
produc
higher
activ
compar
methoxi
substitut
compound
dock
studi
suggest
group
locat
near
pocket
one
oxygen
atom
nitro
group
form
hydrogen
bond
keto
function
pyrazolon
ring
also
found
form
anoth
hydrogen
bond
phenyl
ring
found
wellaccommod
pocket
benzyliden
ring
without
carboxyl
function
lost
activ
therefor
may
assum
hydrogen
bond
interact
import
hydrophob
interact
oxygen
atom
carboxyl
group
form
hydrogen
bond
therefor
apart
pocket
none
aryl
function
exhibit
hydrophob
interact
wherea
three
hydrogen
bond
interact
observ
compound
consid
outlier
observ
eq
increas
valu
dipol
moment
along
xaxi
may
conduc
activ
thu
bulki
substitut
xaxi
molecul
may
favor
activ
compound
tabl
possess
higher
dipol
moment
due
much
bulki
aryl
group
compar
compound
therefor
higher
activ
compound
exhibit
aberr
behavior
thu
consid
outlier
nguyen
et
al
report
promis
sarscov
pro
inhibitor
virtual
screen
fig
tabl
qsar
model
obtain
compound
shown
eq
exhibit
activ
well
correl
hydrophob
molecul
dock
studi
reveal
compound
tabl
good
hydrophob
interact
apart
number
hydrogen
bond
interact
nitro
group
methacrylamid
group
one
oxygen
atom
nitro
group
nitrophenyl
group
found
crucial
moieti
enter
pocket
impart
potent
inhibit
compound
though
possess
higher
valu
hydrophob
less
activ
expect
henc
consid
outlier
peptidomimet
sarscov
pro
inhibitor
tabl
synthes
evalu
akaji
et
al
qsar
model
obtain
eq
indic
activ
control
singl
indic
paramet
use
methyl
substitu
r
posit
posit
coeffici
indic
substitu
would
conduc
activ
reason
may
substitu
might
better
steric
fit
pocket
enzym
form
compound
tabl
consid
outlier
nguyen
et
al
report
flavonoid
pichia
pastori
fig
tabl
sarscov
pro
inhibitori
activ
compound
inhibit
activ
shown
correl
psa
molecul
eq
suggest
highli
polar
molecul
may
better
activ
substitu
like
hydroxi
might
give
better
psa
lead
better
figur
gener
structur
flavonoid
sarscov
pro
inhibitor
activ
also
substitu
might
form
hydrogen
bond
molecular
dock
studi
show
galloyl
group
form
hydrogen
bond
enzym
activ
site
compound
without
b
ring
compound
less
activ
compound
doubl
bond
c
ring
less
activ
compound
though
possess
higher
psa
compound
found
act
outlier
also
observ
rigid
aryl
substitut
hydroxyl
group
compound
better
flexibl
cycloalkyl
substitut
hydroxyl
group
compound
mandadapu
et
al
report
dipeptidyl
aldehyd
amid
potent
noroviru
pro
inhibitor
tabl
qsar
model
obtain
compound
shown
eq
exhibit
hydrophob
compound
may
benefici
sarscov
pro
inhibitori
activ
compound
compound
cyclohexylmethyl
group
appear
potent
compound
might
due
bulki
group
provid
higher
c
log
p
valu
due
better
fit
activ
site
enzym
compound
howev
show
aberr
behavior
thu
consid
outlier
thanigaimalai
et
al
report
seri
dipeptidetyp
sarscov
pro
inhibitor
tabl
qsar
model
obtain
shown
eq
suggest
eq
decreas
valu
sa
may
conduc
enzym
inhibit
howev
volum
molecul
found
exhibit
parabol
relat
enzym
inhibitori
activ
therefor
suggest
increas
volum
may
respons
enhanc
activ
optimum
valu
beyond
valu
activ
would
decreas
thu
indic
molecul
limit
bulk
substitu
limit
bulk
might
favor
activ
thu
indol
deriv
less
bulki
substitut
compound
tabl
result
higher
activ
greater
bulk
compound
compar
indol
analog
oxopyrrolidin
compound
pyrrol
compound
benzothiazol
compound
benzofuran
compound
analog
compar
less
activ
howev
could
explain
model
benzimidazol
analog
compound
higher
activ
compar
benzothiazol
compound
benzofuran
analog
compound
probabl
compound
may
behav
differ
compar
compound
dataset
therefor
compound
consid
outlier
subsequ
studi
thanigaimalai
et
al
report
seri
dipeptidetyp
sarscov
proteas
inhibitor
tabl
whose
activ
shown
control
molar
refract
cmr
polar
volum
pol
vol
compound
eq
sinc
correl
quadrat
respect
cmr
pol
vol
suggest
compound
limit
bulk
polar
may
better
bind
affin
sever
compound
howev
treat
outlier
turlington
et
al
report
seri
n
benzo
n
benzyl
acetamido
phenyl
carboxamid
promis
sarscov
pro
inhibitor
tabl
qsar
model
obtain
compound
eq
suggest
highli
hydrophob
c
log
p
molecul
high
molar
refract
less
mw
conduc
activ
structur
insight
viral
proteas
inhibitor
chapter
n
benzo
n
tabl
report
prior
et
al
suggest
psa
molecul
control
activ
cho
group
xposit
indic
paramet
use
ad
advantag
psa
may
affect
activ
due
polar
interact
molecul
cho
group
might
involv
hydrogen
bond
interact
residu
activ
site
tabl
qsar
model
shown
eq
observ
eq
increas
valu
hydrophob
may
favor
activ
moder
dipol
moment
compound
also
conduc
inhibit
enzym
howev
neg
valu
indic
variabl
use
valu
compound
function
r
posit
indic
substitu
would
prefer
probabl
substitu
might
creat
steric
hindranc
interact
compound
receptor
moham
et
al
recent
report
substitut
pyrazol
substitut
pyrimidin
promis
sarscov
pro
inhibitor
fig
tabl
qsar
model
eq
obtain
compound
simpli
suggest
highli
polar
fraction
molecul
high
valu
xcompon
dipol
moment
x
conduc
activ
galas
et
al
recent
report
seri
dipeptidyl
noroviru
pro
inhibitor
potent
inhibitori
activ
tabl
qsar
model
obtain
inhibitor
shown
eq
equat
simpli
suggest
zcompon
dipol
moment
favor
activ
moder
psa
advers
effect
tabl
qsar
model
obtain
eq
suggest
molecul
optimum
lipophil
valu
impart
higher
activ
activ
may
support
xcompon
dipol
moment
psa
molecul
notwithstand
high
polar
volum
molecul
deliri
activ
activ
shown
correl
two
indic
variabl
valu
indic
presenc
ipropyl
tbutyl
moieti
r
posit
respect
posit
coeffici
paramet
suggest
ipropyl
tbutyl
function
r
posit
favor
inhibitori
activ
compound
behav
aberrantli
therefor
consid
outlier
may
observ
tbutyl
substitut
r
posit
compound
gave
better
activ
ibutyl
substitut
posit
compound
dragovich
et
al
report
seri
michael
acceptor
type
potent
hrv
pro
inhibitor
fig
tabl
qsar
model
eq
exhibit
posit
effect
activ
compound
produc
zcompon
dipol
moment
sa
compound
till
attain
optimum
valu
two
properti
indic
kind
electron
interact
molecul
receptor
dragovich
et
al
report
seri
peptidederiv
potent
hrv
pro
inhibitor
tabl
qsar
model
eq
suggest
activ
would
primarili
control
hydrophob
molecul
polar
volum
total
dipol
moment
compound
would
also
help
increas
activ
compound
indic
paramet
indic
presenc
ibutyl
moieti
r
posit
neg
coeffici
suggest
ibutyl
function
favor
r
posit
might
creat
steric
problem
dragovich
et
al
report
ketomethylen
group
contain
peptidebas
hrv
pro
inhibitor
tabl
observ
eq
decreas
valu
dipol
moment
along
yaxi
may
increas
activ
model
also
show
import
two
indic
variabl
use
valu
uniti
ibutyl
ipropyl
substitu
r
posit
respect
neg
coeffici
suggest
ibutyl
group
conduc
activ
posit
coeffici
suggest
ipropyl
group
would
favor
activ
fact
observ
ibutyl
substitut
compound
ipropyl
substitut
compound
dragovich
et
al
report
hrv
pro
inhibitor
tabl
qsar
model
shown
eq
obtain
suggest
high
polar
compound
xdirect
detriment
inhibit
potenc
compound
simpl
structureact
relationship
studi
continu
dragovich
et
al
also
report
tripeptidyl
nmethyl
amino
acid
hrv
pro
inhibitor
tabl
qsar
model
obtain
eq
suggest
activ
total
govern
total
dipol
moment
compound
indic
strong
electron
interact
molecul
receptor
howev
keton
contain
tripeptidyl
hrv
pro
inhibitor
tabl
report
dragovich
et
al
qsar
model
eq
exhibit
import
zcompon
dipol
moment
compound
zdirect
polar
compound
may
favor
electron
interact
receptor
webber
et
al
report
depsipeptidyl
hrv
pro
inhibitor
tabl
qsar
model
obtain
shown
eq
model
suggest
case
polar
volum
molecul
conduc
activ
p
c
p
p
c
p
contain
peptidomimet
promis
hrv
pro
inhibitor
tabl
report
dragovich
et
al
qsar
model
eq
howev
suggest
sa
molecul
favor
activ
probabl
dispers
interact
activ
surfac
molecul
receptor
howev
high
sa
shown
detriment
activ
probabl
steric
problem
tabl
inhibitor
qsar
model
eq
indic
activ
compound
simpli
depend
upon
presenc
absenc
group
chromen
ring
rposit
compound
two
indic
variabl
former
valu
indic
presenc
group
latter
valu
uniti
indic
presenc
chromen
ring
rposit
posit
coeffici
variabl
indic
favor
contribut
either
substitu
might
steric
interact
activ
site
enzym
dragovich
et
al
report
seri
contain
peptidomimet
hrv
pro
inhibitor
tabl
qsar
model
obtain
compound
shown
eq
model
suggest
less
bulki
molecul
small
xcompon
dipol
moment
favor
simultan
high
valu
psa
molecul
may
conduc
activ
posit
coeffici
indic
variabl
defin
valu
uniti
benzyl
substitu
r
posit
indic
substitu
desir
better
activ
compound
benzyl
group
might
steric
interact
receptor
total
qsar
model
sarscov
pro
inhibitor
hrv
pro
inhibitor
report
get
insight
relat
enzym
inhibitori
activ
antivir
compound
physicochem
structur
properti
qsar
model
exhibit
physicochem
paramet
dipol
moment
psa
polar
volum
hydrophob
molar
refract
sa
molecular
volum
compound
play
crucial
role
control
sarscov
pro
hrv
pro
inhibitori
activ
moreov
structur
indic
variabl
found
play
import
role
inhibit
enzym
mani
case
dipol
moment
psa
found
domin
factor
bulk
inhibitor
flexibl
polar
also
appear
play
crucial
role
inhibit
enzym
qsar
model
exhibit
direct
correl
dipol
moment
pro
pro
inhibitori
activ
major
show
posit
effect
dipol
moment
activ
show
neg
effect
posit
neg
effect
may
attribut
orient
inhibitor
molecul
activ
site
enzym
psa
polar
inhibitor
import
factor
found
case
influenc
activ
posit
coeffici
correl
indic
attract
electron
interact
molecul
enzym
neg
coeffici
indic
repuls
interact
mani
case
polar
volum
found
govern
activ
polar
volum
also
indic
attract
repuls
dispers
interact
molecul
receptor
among
hydrophob
molecul
role
drugreceptor
interact
hydrophob
found
play
import
role
enzym
activ
site
hydrophob
pocket
play
import
role
activ
site
case
bulki
portion
molecul
tri
occupi
hydrophob
pocket
may
hydrophob
interact
molecular
volum
mw
molar
refract
sometim
becom
synonym
hydrophob
properti
molecul
found
relat
hydrophob
crucial
activ
mean
inhibitorenzym
interact
involv
dispers
interact
qsar
model
discuss
may
great
help
design
new
potent
compound
given
categori
sarscov
pro
hrv
pro
inhibitor
